Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
News|Articles|January 9, 2026
5 Key Health Care Changes During Trump’s First Year Back in Office
Author(s)Laura Joszt, MA
Fact checked by: Christina Mattina
President Donald J. Trump's health care overhaul during the first year of his second term reshapes Medicaid, vaccine policies, and drug pricing.
Advertisement
Advertisement
In 2025, the Trump administration launched a sweeping overhaul of the American health care landscape, marked by the enactment of the landmark One Big Beautiful Bill and a series of transformative executive actions. From the codification of stringent federal Medicaid work requirements to a radical restructuring of the national vaccine schedule under HHS Secretary Robert F. Kennedy Jr, these shifts represent a fundamental departure from the previous administration’s focus on entitlement and expanded coverage.
Related to this article
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Advertisement
Advertisement